- Home
- SBSI vs PHAT Comparison
SBSI vs PHAT Comparison
Compare SBSI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBSI | PHAT |
|---|---|---|
| Founded | 1960 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.3M | 894.0M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SBSI | PHAT |
|---|---|---|
| Price | $30.40 | $10.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $35.50 | $19.50 |
| AVG Volume (30 Days) | 91.6K | ★ 940.4K |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 2.29 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $28.87 | $92.15 |
| Revenue Next Year | $5.82 | $59.79 |
| P/E Ratio | $13.53 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $25.85 | $2.21 |
| 52 Week High | $34.37 | $18.31 |
Technical Indicators
Market Signals| Indicator | SBSI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 43.50 |
| Support Level | $30.06 | $10.06 |
| Resistance Level | $31.38 | $12.62 |
| Average True Range (ATR) | 0.67 | 0.67 |
| MACD | 0.13 | 0.08 |
| Stochastic Oscillator | 55.42 | 35.00 |
Price Performance
Historical ComparisonAbout SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.